These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry. Dreyer L; Magyari M; Laursen B; Cordtz R; Sellebjerg F; Locht H Ann Rheum Dis; 2016 Apr; 75(4):785-6. PubMed ID: 26698850 [No Abstract] [Full Text] [Related]
4. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis. Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066 [TBL] [Abstract][Full Text] [Related]
5. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Robinson WH; Genovese MC; Moreland LW Arthritis Rheum; 2001 Sep; 44(9):1977-83. PubMed ID: 11592357 [No Abstract] [Full Text] [Related]
6. Demyelinating events in rheumatoid arthritis after drug exposures. Bernatsky S; Renoux C; Suissa S Ann Rheum Dis; 2010 Sep; 69(9):1691-3. PubMed ID: 19628820 [TBL] [Abstract][Full Text] [Related]
7. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Gregory AP; Dendrou CA; Attfield KE; Haghikia A; Xifara DK; Butter F; Poschmann G; Kaur G; Lambert L; Leach OA; Prömel S; Punwani D; Felce JH; Davis SJ; Gold R; Nielsen FC; Siegel RM; Mann M; Bell JI; McVean G; Fugger L Nature; 2012 Aug; 488(7412):508-511. PubMed ID: 22801493 [TBL] [Abstract][Full Text] [Related]
8. Demyelinating polyneuropathy after long-term treatment with infliximab. Nakamura K; Hamaguchi T; Yamada M Int J Rheum Dis; 2017 Nov; 20(11):1781-1782. PubMed ID: 26179198 [No Abstract] [Full Text] [Related]
9. [Neurological adverse events under anti-TNF alpha therapy]. Cohen M; Baldin B; Thomas P; Lebrun C Rev Neurol (Paris); 2012 Jan; 168(1):33-9. PubMed ID: 22098827 [TBL] [Abstract][Full Text] [Related]
10. [TNF-alpha inhibitors and demyelinating disease]. Böttiger Y Lakartidningen; 2007 Nov 7-13; 104(45):3384. PubMed ID: 18062640 [No Abstract] [Full Text] [Related]
11. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Seitz M; Wirthmüller U; Möller B; Villiger PM Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636 [TBL] [Abstract][Full Text] [Related]
12. Antinuclear antibodies are associated with tumor necrosis factor receptor I gene polymorphism in patients with rheumatoid arthritis. Glossop JR; Dawes PT; Mattey DL Clin Exp Rheumatol; 2011; 29(4):609-15. PubMed ID: 21813053 [TBL] [Abstract][Full Text] [Related]
13. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Clemente RE Scand J Rheumatol; 2007; 36(3):244-5; author reply 245. PubMed ID: 17657687 [No Abstract] [Full Text] [Related]
14. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Tanno M; Nakamura I; Kobayashi S; Kurihara K; Ito K Clin Rheumatol; 2006 Nov; 25(6):929-33. PubMed ID: 16328088 [TBL] [Abstract][Full Text] [Related]
15. [Apperceptive form visual agnosia caused by anti-TNFalpha therapy to rheumatoid arthritis]. Kobayashi S; Tanno M; Nakamura I; Ito K; Ugawa Y Rinsho Shinkeigaku; 2007; 47(2-3):96-9. PubMed ID: 17511276 [TBL] [Abstract][Full Text] [Related]
16. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Toonen EJ; Coenen MJ; Kievit W; Fransen J; Eijsbouts AM; Scheffer H; Radstake TR; Creemers MC; de Rooij DJ; van Riel PL; Franke B; Barrera P Ann Rheum Dis; 2008 Aug; 67(8):1174-7. PubMed ID: 18385279 [TBL] [Abstract][Full Text] [Related]
17. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Kary S; Worm M; Audring H; Huscher D; Renelt M; Sörensen H; Ständer E; Maass U; Lee H; Sterry W; Burmester GR Ann Rheum Dis; 2006 Mar; 65(3):405-7. PubMed ID: 16150791 [TBL] [Abstract][Full Text] [Related]
18. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. Chatzikyriakidou A; Georgiou I; Voulgari PV; Venetsanopoulou AI; Drosos AA Rheumatology (Oxford); 2007 Jun; 46(6):1034-5. PubMed ID: 17409133 [No Abstract] [Full Text] [Related]
19. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Wendling D; Balblanc JC; Brousse A; Lohse A; Lehuede G; Garbuio P; Toussirot E; Auge B; Jacques D Ann Rheum Dis; 2005 Sep; 64(9):1378-9. PubMed ID: 16100348 [No Abstract] [Full Text] [Related]